论文部分内容阅读
目的:探讨混合抗球蛋白反应试验(MAR)与常规体外受精-胚胎移植(IVF-ET)治疗的关系。方法:回顾性分析562例第1次行IVF治疗不孕患者的临床资料,按照MAR检测结果将IVF周期分成4个区间组:<10%,10%~30%,30%~50%,>50%,分析各组间受精率、胚胎发育及临床妊娠情况。结果:540个IVF移植周期中共获得279例妊娠,周期妊娠率为51.7%。MAR>50%组的受精率显著低于其余各组(P<0.05),而各组间女方年龄、不孕年限、受精失败率、精子密度、精子活动率、正常形态精子百分率、优质胚胎率、胚胎种植率、临床妊娠率及流产率比较则均无统计学差异(P>0.05)。结论:MAR检测结果在预测IVF受精结局中有一定的价值,但与IVF治疗的临床妊娠结局无关。
Objective: To investigate the relationship between mixed antiglobulin test (MAR) and routine in vitro fertilization-embryo transfer (IVF-ET). Methods: The clinical data of 562 patients with infertility treated with IVF for the first time were retrospectively analyzed. The IVF cycles were divided into four intervals according to the MAR test results: 10%, 10% -30%, 30% -50% 50%, analysis of fertilization rates between groups, embryonic development and clinical pregnancy. Results: A total of 279 pregnancies were obtained in 540 IVF transplantation cycles and the pregnancy rate was 51.7%. The fertilization rate of MAR> 50% group was significantly lower than that of the other groups (P <0.05), while the female age, the duration of infertility, the failure rate of fertilization, sperm density, sperm motility, percentage of normal spermatozoa, , Embryo implantation rate, clinical pregnancy rate and abortion rate were no statistical difference (P> 0.05). Conclusion: The results of MAR test have some value in predicting the IVF fertilization outcome, but have no relation with clinical pregnancy outcome of IVF treatment.